Profile
Andrew Partridge is currently the Chief Commercial Officer & Executive VP at Turning Point Therapeutics, Inc. He previously worked as the Executive Director-Sales & Oncology Business Unit at Amgen, Inc. from 2003 to 2013.
From 2013 to 2018, he worked as the Regional Head-North America Commercial at Vertex Pharmaceuticals, Inc. Prior to his current position, he was the Chief Commercial Officer & Executive VP at Centrexion Therapeutics Corp.
from 2018 to 2020.
Andrew Partridge active positions
| Companies | Position | Start |
|---|---|---|
| TURG POIN | Corporate Officer/Principal | 2020-07-12 |
Former positions of Andrew Partridge
| Companies | Position | End |
|---|---|---|
| CENTREXION THERAPEUTICS CORPORATION | Corporate Officer/Principal | 2020-07-01 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 2018-10-31 |
| AMGEN INC. | Sales & Marketing | 2012-12-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 2 |
|---|---|
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Its product pipeline includes CNTX-4975, CNTX-0290, CNTX-6970, CNTX-2022, CNTX-6016, and intrathecal platform. The company was founded by Sol J. Barer and Jeffrey B. Kindler in February 2013 and is headquartered in Boston, MA. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Andrew Partridge
